MiMedx Group Inc
Latest MiMedx Group Inc News and Updates

How Did Ziopharm Keep XBI from Losing More Ground?
Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.

Analyst Ratings for Globus Medical and Its Peers in February
Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold.”

Behind MiMedx Group’s Recent Financial Performance
In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.

Why the Physician Office Pain Management Market Matters to MiMedx
Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.

Understanding MiMedx Group’s Zealous Focus on Sales
MiMedx focuses on marketing efforts to increase revenues. The company has at its disposal a sales force of 320 professionals.

MiMedx Group on the Street: Analyst Recommendations in January
Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.